

Registered number: 761912

Jamp Pharma Ireland Limited

Directors' Report and Financial Statements

For the financial period from incorporation on 12 April 2024 to 31 March 2025

Jamp Pharma Ireland Limited

Company Information

Directors	Kang Hyuk Lee (appointed 12 April 2024) Marc-Andre Huot (appointed 12 April 2024) Shane O'Connell (appointed 31 December 2025)
Company secretary	HMP Secretarial Limited (appointed 12 April 2024)
Registered number	761912
Registered office	Riverside one Sir John Rogerson's Quay Dublin Dublin 2 D02 X576
Independent auditor	BDO Statutory Audit Firm Block 3 Miesian Plaza 50-58 Baggot Street Lower Dublin 2 D02 Y754

Jamp Pharma Ireland Limited

Contents

	Page
Directors' Report	1 - 2
Directors' Responsibilities Statement	3
Independent Auditor's Report	4 - 6
Statement of Comprehensive Income	7
Balance Sheet	8
Statement of Changes in Equity	9
Notes to the Financial Statements	10 - 12

Jamp Pharma Ireland Limited

Directors' Report For the Financial Period Ended 31 March 2025

The directors present their annual report and the audited financial statements for the financial period from the date of incorporation on 12 April 2024 to 31 March 2025.

Principal activities

The principal activity of the Company is wholesale of pharmaceutical goods.

Results and dividends

The loss for the financial period amounted to €19,374.

No dividends were paid or provided for during the current financial period. No final dividend has been proposed.

Directors

The directors who served during the financial period were:

Kang Hyuk Lee (appointed 12 April 2024)

Marc-Andre Huot (appointed 12 April 2024)

Accounting records

The measures taken by the directors to ensure compliance with the requirements of Sections 281 to 285 of the Companies Act 2014 with regard to the keeping of accounting records, are the employment of appropriately qualified accounting personnel and the maintenance of computerised accounting systems. The Company's accounting records are maintained at the Company's registered office at Riverside one, Sir John Rogerson's Quay, Dublin, Dublin 2, D02 X576.

Statement on relevant audit information

Each of the persons who are directors at the time when this Directors' Report is approved has confirmed that:

- so far as the director is aware, there is no relevant audit information of which the Company's auditor is unaware; and
- the director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

Post balance sheet events

There have been no significant events affecting the Company since the period end.

Jamp Pharma Ireland Limited

**Directors' Report (continued)
For the Financial Period Ended 31 March 2025**

Auditor

The auditor, BDO, were appointed, in accordance with section 383(2) of the Companies Act 2014.

This report was approved by the board on 27 February 2026 and signed on its behalf.

Signé par :

Marc-André Huot



Nom du signataire : Marc-André Huot

Motif de la signature : J'approuve ce document

Heure de signature : 2026-03-02 | 8:47:22 AM EST

E3CC224E40CE4AB7A26C1A778B645B86

Marc-Andre Huot
Director

Kang Hyuk Lee
Director

Jamp Pharma Ireland Limited

Directors' Responsibilities Statement For the Financial Period Ended 31 March 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with Irish law and regulations.

Irish company law requires the directors to prepare the financial statements for each financial year. Under the law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' .

Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the Company as at the financial year end date, of the profit or loss for that financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the Company's financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for ensuring that the Company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the Company, enable at any time the assets, liabilities, financial position and profit or loss of the Company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Jamp Pharma Ireland Limited

Independent Auditor's Report to the Members of Jamp Pharma Ireland Limited

Report on the audit of the financial statements

Opinion

We have audited the financial statements of Jamp Pharma Ireland Limited (the 'Company') for the financial period ended 31 March 2025, which comprise the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the notes to the financial statements, including a summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland issued in the United Kingdom by the Financial Reporting Council .

In our opinion, the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the Company as at 31 March 2025 and of its loss for the financial period then ended;
- have been properly prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority ('IAASA'), and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Jamp Pharma Ireland Limited

Independent Auditor's Report to the Members of Jamp Pharma Ireland Limited (continued)

Other information

The directors are responsible for the other information. The other information comprises the information included in the Annual report, other than the financial statements and our Auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2014

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the Directors' Report is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with the Companies Act 2014.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

In our opinion the accounting records of the Company were sufficient to permit the financial statements to be readily and properly audited, and the financial statements are in agreement with the accounting records.

Matters on which we are required to report by exception

Based on the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified any material misstatements in the Directors' Report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of sections 305 to 312 of the Act, which relate to disclosures of directors' remuneration and transactions are not complied with by the Company. We have nothing to report in this regard.

Respective responsibilities

Responsibilities of directors for the financial statements

As explained more fully in the Directors' Responsibilities Statement on page 3, the directors are responsible for the preparation of the financial statements in accordance with the applicable financial reporting framework that give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Jamp Pharma Ireland Limited

Independent Auditor's Report to the Members of Jamp Pharma Ireland Limited (continued)

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on IAASA's website at: https://iaasa.ie/getmedia/b2389013-1cf6-458b-9b8f-a98202dc9c3a/Description_of_auditors_responsibilities_for_audit.pdf. This description forms part of our auditor's report.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the Company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



Ronan Harbourne
for and on behalf of
BDO
Statutory Audit Firm
Block 3
Miesian Plaza
50-58 Baggot Street Lower
Dublin 2
D02 Y754

27 February 2026

Jamp Pharma Ireland Limited

**Statement of Comprehensive Income
For the Financial Period Ended 31 March 2025**

	Period ended 31 March 2025 €
Administrative expenses	(19,374)
Operating loss	(19,374)
Tax on loss	-
Loss for the financial period	(19,374)

There were no recognised gains and losses for 2025 other than those included in the Statement of Comprehensive Income.

Jamp Pharma Ireland Limited

**Balance Sheet
As at 31 March 2025**

	Note		2025 €
Current liabilities			
Debtors: amounts falling due within one year	5	7	
		<hr style="width: 100%;"/>	
		7	
Creditors: amounts falling due within one year	6	(19,374)	
		<hr style="width: 100%;"/>	
Net current liabilities			(19,367)
Net liabilities			(19,367)
			<hr style="width: 100%;"/>
Capital and reserves			
Called up share capital presented as equity			7
Profit and loss account			(19,374)
			<hr style="width: 100%;"/>
Shareholders' deficits			(19,367)
			<hr style="width: 100%;"/>

The financial statements were approved and authorised for issue by the board:

Signé par :

 Nom du signataire : Marc-André Huot
 Motif de la signature : J'approuve ce document
 Heure de signature : 2026-03-02 | 8:47:22 AM EST
 E3CC224E40CE4AB7A26C1A778B645B86

Marc-Andre Huot
Director


Kang Hyuk Lee
Director

Date: 27 February 2026

The notes on pages 10 to 12 form part of these financial statements.

Jamp Pharma Ireland Limited

**Statement of Changes in Equity
For the Financial Period Ended 31 March 2025**

	Called up share capital	Profit and loss account	Total equity
	€	€	€
At 12 April 2024	-	-	-
Comprehensive income for the financial period			
Loss for the financial period	-	(19,374)	(19,374)
Total comprehensive income for the financial period	-	(19,374)	(19,374)
Contributions by and distributions to owners			
Shares issued during the financial period	7	-	7
At 31 March 2025	7	(19,374)	(19,367)

The notes on pages 10 to 12 form part of these financial statements.

Jamp Pharma Ireland Limited

Notes to the Financial Statements For the Financial Period Ended 31 March 2025

1. General information

These financial statements comprising the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes constitute the individual financial statements of Jamp Pharma Ireland Limited for the financial period from incorporation on 12 April 2024 to 31 March 2025.

Jamp Pharma Ireland Limited is a private company limited by shares (registered under Part 2 of the Companies Act 2014), incorporated in the Republic of Ireland. The registered office is at Riverside one, Sir John Rogerson's Quay, Dublin, Dublin 2, D02 X576 which is also the principal place of business of the Company. The nature of the Company's operations and its principal activities are set out in the Directors' Report on pages 1 - 2.

The functional currency of Jamp Pharma Ireland Limited is considered to be Euro because that is the currency of the primary economic environment in which the Company operates.

2. Accounting policies

2.1 Basis of preparation of financial statements

The Financial Statements have been prepared in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and Irish statute comprising of the Companies Act 2014. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The Company has availed of the exemption from preparing a cashflow statement by virtue of its size.

The following principal accounting policies have been applied:

2.2 Going concern

The Company incurred a loss of €19,374 during the financial period ended 31 March 2025 and had a net liability position of €19,367 at the end of the financial period. This is the first year of the Company's operations. The Company continues to trade as a going concern in order to continue to operate for the foreseeable future.

Jamp International Inc. has agreed to provide continued financial support to ensure that the Company can meet its liabilities as they fall due, for a period of at least twelve months from the date of approval of these financial statements. The directors have satisfied themselves that the ultimate parent company has the necessary financial resources to provide this support during this period, should it be required. Accordingly, the directors believe it is appropriate to continue to adopt the going concern basis of accounting.

The financial statements do not include any adjustments that would arise if the Company were unable to continue as a going concern.

2.3 Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.4 Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Jamp Pharma Ireland Limited

Notes to the Financial Statements For the Financial Period Ended 31 March 2025

2. Accounting policies (continued)

2.5 Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities

All financial assets and liabilities are initially measured at transaction price (including transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when:

- a) the contractual rights to the cash flows from the financial asset expire or are settled,
- b) the Company transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or
- c) the Company, despite having retained some significant risks and rewards of ownership, has transferred control of the asset to another party and the other party has the practical ability to sell the asset in its entirety to an unrelated third party and is able to exercise that ability unilaterally and without needing to impose additional restrictions on the transfer.

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

3. Judgements in applying accounting policies and key sources of estimation uncertainty

The preparation of these financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses.

Judgements and estimates are continually evaluated and are based on historical experiences and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The Company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results.

Given the limited activity of the Company, the directors consider any judgements, estimates and assumptions as outlined above to be of a nature which has no material impact on the reported assets, liabilities, income and expenditure.

4. Employees

The Company has no employees other than the directors, who did not receive any remuneration.

Jamp Pharma Ireland Limited

Notes to the Financial Statements For the Financial Period Ended 31 March 2025

5. Debtors

	2025 €
Other debtors	7
	<u>7</u>

6. Creditors: amounts falling due within one year

	2025 €
Trade creditors	10,245
Amounts owed to group undertakings	2,629
Accruals	6,500
	<u>19,374</u>

Amounts owed to group undertakings are interest free, unsecured and repayable on demand.

7. Share capital

	2025 €
Authorised, allotted, called up and fully paid	
10 ordinary shares of CAD1 each	7
	<u>7</u>

On incorporation, the company issued 10 ordinary shares of CAD1 each at par.

8. Related party transactions

The Company is availing of the exemption granted under FRS 102 from disclosing information relating to transactions with other wholly-owned subsidiaries within the Group.

9. Post balance sheet events

There have been no significant events affecting the Company since the period end.

10. Controlling party

In the opinion of the directors the company's ultimate parent company and controlling party is Jamp Pharma International Inc., a company incorporated and operating in Canada.

11. Approval of financial statements

The board of directors approved these financial statements for issue on 27 February 2026